DalsnaFinance › Analyst accuracy › All targets
Every price target we have verified from published news, newest first: 22 targets from H.C. Wainwright. Each one shows the article it came from and links to its full entry, and is judged on the close on the date it comes due. “At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target.
Showing targets from H.C. Wainwright only. All targets H.C. Wainwright’s record →
H.C. Wainwright initiated coverage on Liquidia Technologies (NASDAQ:LQDA) with a buy rating and a price target of $76.00.
This development has led to H.C. Wainwright reiterating a Buy rating with a $25.00 price target
H.C. Wainwright reiterates Buy on Alpha Cognition stock at $20
H.C. Wainwright reiterates buy rating on Strategy with $250 price target
H.C. Wainwright reiterated a Buy rating and $19.00 price target on Brainsway
H.C. Wainwright reiterated a Buy rating and $220.00 price target on Insmed
H.C. Wainwright lowered its price target on Balchem (NASDAQ:BCPC) to $210 from $215 while maintaining a Buy rating.
H.C. Wainwright reiterated a Buy rating and $75 price target on UroGen Pharma
H.C. Wainwright raised its price target on Rhythm Pharmaceuticals stock (NASDAQ:RYTM) to $130 from $105
H.C. Wainwright raised its price target on Kodiak Sciences Inc. (NASDAQ:KOD) to $126 from $96
H.C. Wainwright reiterated a Buy rating and $15.00 price target on Korro Bio Inc. following the company's announcement that it has dosed the first cohort of participants in its Phase 1/2 clinical trial for KRRO-121.
H.C. Wainwright lowered its price target on Liquidia Technologies (NASDAQ:LQDA) to $58 from $130 while maintaining a Buy rating on Wednesday.
H.C. Wainwright lowered its price target on Foghorn Therapeutics Inc. to $5.00 from $13.00 while maintaining a Buy rating
H.C. Wainwright reiterated its Buy rating on Vir Biotechnology, maintaining a price target of $20.00
reiterated a Buy rating with a $140 price target, highlighting the competitive efficacy and clean safety profile
H.C. Wainwright reiterated a Buy rating with a $58 price target.
H.C. Wainwright raised its price target on Incyte Corp. (NASDAQ:INCY) to $152 from $150 while maintaining a Buy rating.
lowered its price target on Acadia Pharmaceuticals stock (NASDAQ:ACAD) to $33 from $37
H.C. Wainwright reiterated a Buy rating on Vertex shares (NASDAQ:VRTX) and maintained its $641.00 price target on Monday.
H.C. Wainwright reiterated its Buy rating with a $50 price target
H.C. Wainwright reiterated its Buy rating on the company, maintaining a $12.00 price target
H.C. Wainwright raised its price target on Biogen Inc. to $251 from $237 while maintaining a Buy rating
Retracted targets, ones we found we had misreported, are not listed here and count toward nothing; each firm's row on the analyst accuracy page lists its own under "Retracted". These are facts about what each firm published, not recommendations from Dalsna Finance.
Full methodology: how targets are collected, scored, ranked and corrected, what each field means, and how to cite the data.